10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) by 66.67 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $150.843 million which beat the analyst consensus estimate of $146.355 million by 3.07 percent. This is a 2.61 percent decrease over sales of $154.883 million the same period last year.